Geom Therapeutics

Geom Therapeutics Overview

  • Founded
  • 2016
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $4.36M
Latest Deal Amount
  • Investors
  • 1

Geom Therapeutics General Information


Developer of novel antibiotics created to provide broad spectrum coverage including activity against multi-drug resistant Pseudomonas and Acinetobacter. The company's GT- 1 provides superior survival to ceftazidime and doripenem in resistant P. aeruginosa systemic infection model, enabling patients to get treated with multidrug-resistant gram-negative infections.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 826A Vallejo Street
  • San Francisco, CA 94133
  • United States
+1 (415) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Geom Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 08-Apr-2017 $4.36M 00.000 Completed Startup
1. Merger/Acquisition 07-Jul-2016 Completed Startup

Geom Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Dirk Thye MD Chief Executive Officer & Executive Chairman

Geom Therapeutics Board Members (5)

Name Representing Role Since
Cooper Collins Geom Therapeutics Board Member 000 0000
Dirk Thye MD Self Chief Executive Officer & Executive Chairman 000 0000
Dov Goldstein Geom Therapeutics Board Member 000 0000
Sejin Park Geom Therapeutics Board Member 000 0000
Yong-Zu Kim Geom Therapeutics Board Member 000 0000

Ready to get started?

Request a free trial